Fred Alger Management Inc. lowered its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 77.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,100 shares of the biopharmaceutical company’s stock after selling 69,997 shares during the period. Fred Alger Management Inc.’s holdings in Alexion Pharmaceuticals were worth $2,404,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Delpha Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals during the fourth quarter worth $102,000. Valeo Financial Advisors LLC acquired a new position in shares of Alexion Pharmaceuticals during the third quarter worth $147,000. Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals during the third quarter worth $156,000. Beacon Investment Advisory Services Inc. acquired a new position in shares of Alexion Pharmaceuticals during the third quarter worth $201,000. Finally, Invictus RG acquired a new position in shares of Alexion Pharmaceuticals during the third quarter worth $202,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.
In other news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Julie O’neill sold 1,625 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $119.83, for a total transaction of $194,723.75. The disclosure for this sale can be found here. Insiders sold 31,253 shares of company stock valued at $3,656,229 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 9.5% compared to the same quarter last year. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
A number of brokerages recently commented on ALXN. Cowen reiterated a “buy” rating and set a $163.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday. Raymond James Financial reiterated an “outperform” rating and set a $130.00 target price (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. UBS Group downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. Credit Suisse Group reiterated an “outperform” rating and set a $147.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, January 18th. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $154.64.
TRADEMARK VIOLATION NOTICE: “Fred Alger Management Inc. Has $2.40 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3259540/fred-alger-management-inc-has-2-40-million-position-in-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.